New drug ABBV-519 enters first human tests for lupus and arthritis

NCT ID NCT07607964

First seen May 31, 2026 · Last updated Jun 13, 2026 · Updated 4 times

Summary

This early-stage study tests a single dose of ABBV-519 in about 30 adults with moderate lupus or rheumatoid arthritis. The goal is to check how the drug moves through the body, how it affects immune cells, and whether it is safe. Participants will be followed for about a year to monitor side effects and immune response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Discovery Health Research Center /ID# 279691

    RECRUITING

    Plantation, Florida, 33317, United States

  • Epic Medical Research /ID# 279180

    RECRUITING

    Red Oak, Texas, 75154, United States

  • Finlay Medical Research - Greenacres /ID# 278380

    RECRUITING

    Greenacres City, Florida, 33467, United States

  • Solace Research /ID# 279155

    RECRUITING

    Tustin, California, 92780, United States

  • UCLA Health West Medical Campus /ID# 282811

    WITHDRAWN

    Los Angeles, California, 90095, United States

Conditions

Explore the condition pages connected to this study.